Pegylated-Interferon-Alpha 2a in Clinical Practice: How to Manage Patients Suffering from Side Effects
February 2011
in “
Expert Opinion on Drug Safety
”
Studysummary This review discusses adverse effects associated with pegylated IFN therapy for chronic hepatitis C and highlights the potential of new antiviral drugs to reduce side effects and improve treatment adherence, but reports no new clinical results.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on hdl.handle.net →